Patents Represented by Attorney Michael C. Badia

Find this attorney in the Justia Lawyer Directory

  • Quinazolines useful as modulators of ion channels
    Patent number: 7678802
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: March 16, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jesus E. Gonzalez, III, Dean Mitchell Wilson, Andreas Peter Termin, Peter Diederik Jan Grootenhuis, Yulian Zhang, Benjamin John Petzoldt, Lev Tyler Dewey Fanning, Timothy Donald Neubert, Roger Tung, Esther Martinborough, Nicole Zimmerman
  • Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
    Patent number: 7659309
    Abstract: The present invention relates to polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester, processes therein, pharmaceutical compositions thereof, and uses therewith.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: February 9, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Todd Blythe, Philip Nyce, Yong Cui
  • Gyrase inhibitors and uses thereof
    Patent number: 7618974
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: November 17, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean P. Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
    Patent number: 7605270
    Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (Compound 1): and pharmaceutical compositions thereof. The present invention also relates to processes to prepare compound 1 and pharmaceutical compositions thereof. Compound 1 is an IMPDH inhibitor useful in treating IMPDH-mediated diseases such as immune system related diseases, viral diseases, and cancers.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: October 20, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Todd Blythe, Alex Eberlin, Michael Hurrey, David Jonaitis, Philip Nyce, Stephan Parent, John Snoonian
  • Gyrase inhibitors and uses thereof
    Patent number: 7582641
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: November 11, 2004
    Date of Patent: September 1, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Gyrase inhibitors and uses thereof
    Patent number: 7569591
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: August 4, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Processes for preparing biaryl ureas and analogs thereof
    Patent number: 7544810
    Abstract: The present invention relates to processes for preparing biaryl ureas derivatives and analogs thereof. The invention also provides compounds useful as intermediates in the processes of the present invention. The process is useful for preparing compounds that inhibit IMPDH.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: June 9, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Graham Ansell, Todd Blythe, Andrew Jones, Benjamin Littler, Adam Looker, Philip Nyce, John Snoonian
  • Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4- (oxazol-5-yl)phenyl) ureido)phenyl) ethylcarbamate
    Patent number: 7504515
    Abstract: The present invention relates to polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethylcarbamate (Compound 1): pharmaceutical compositions thereof. The present invention also relates to processes to prepare compound 1 and pharmaceutical compositions thereof. Compound 1 is an IMPDH inhibitor useful in treating IMPDH-mediated diseases such as immune system related diseases, viral diseases, and cancers.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: March 17, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Todd Blythe, Petinka Vlahova
  • Gyrase inhibitors and uses thereof
    Patent number: 7495014
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: February 24, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiensheng Wang, Arnaud LeTiran, Joseph Drumm
  • Inhibitors of TACE
    Patent number: 7485664
    Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: February 3, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Bandarage, Jon H. Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Tiansheng Wang, Shi-Kai Tian
  • Inhibitors of phosphatases
    Patent number: 7439249
    Abstract: The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: October 21, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeffrey O. Saunders, Gregory F. Miknis, Alexandre J. Buckmelter, Kevin W. Hunt, James F. Blake, Guy P. A. Vigers, Xicheng Sun
  • Sulfhydantoins as phosphate isosteres
    Patent number: 7432292
    Abstract: The present invention relates to novel phosphate isosteres. The invention relates to compounds having a sulfhydantoin or a reverse sulfhydantoin moiety, uses thereof, and related methods. The present invention relates to compounds of formula I or II: or pharmaceutically acceptable salts thereof; wherein Q, T, m, and X are as described herein. These compounds are inhibitors of phosphatases, particularly inhibitors of SHP-2. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing these compounds and compositions in the treatment of various phosphatase-mediated diseases.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: October 7, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeffrey O. Saunders, Gregory F. Miknis, James F. Blake
  • Gyrase inhibitors and uses thereof
    Patent number: 7414046
    Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: August 19, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Anne-Laure Grillot, Paul Charifson, Dean Stamos, Yusheng Liao, Michael Badia, Martin Trudeau
  • Compositions comprising IMPDH inhibitors and uses thereof for treating HCV infection
    Patent number: 7371372
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor selected from VX-148 or VX-944, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: May 13, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Pravin Chaturvedi, Ene Ette
  • Benzimidazoles useful as modulators of ion channels
    Patent number: 7309716
    Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: December 18, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
  • Optimal compositions and methods thereof for treating HCV infections
    Patent number: 6824769
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: November 30, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Pravin Chaturvedi, Ene Ette
  • Caspase inhibitors and uses thereof
    Patent number: 6800619
    Abstract: Described herein are compounds that are useful as caspase inhibitors having the formula: wherein Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CN, CHN2, R, or CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, or an aralkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; and R3 is hydrogen, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted C1-6 aliphatic group, R4 is an optionally substituted group selected from an aryl group or a heterocyclyl group, or R3 and R4 taken together with the nitrogen to which they are attached optionally form a substituted or unsubstituted monocyclic, bicyclic or tricyclic ring.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: October 5, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Ronald Knegtel, Michael Mortimore
  • Carbamate caspase inhibitors and uses thereof
    Patent number: 6689784
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 and R5 are taken together with the intervening nitrogen to form heterocyclic ring and R is as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1&bgr; secretion.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: February 10, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Ronald Knegtel, Michael Mortimore, David Kay, Julian M. C. Golec
  • Gyrase inhibitors and uses thereof
    Patent number: RE40245
    Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: April 15, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Anne-Laure Grillot, Paul S. Charifson, Dean Stamos, Yusheng Liao, Michael C. Badia, Martin Trudeau